Abstract
The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.
| Original language | English |
|---|---|
| Pages (from-to) | 1143-1149 |
| Number of pages | 7 |
| Journal | Infection and Immunity |
| Volume | 70 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2002 Mar 4 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres. / Seo, Jun Young; Seong, Seung Yong; Ahn, Byung-Yoon; Kwon, Ick Chan; Chung, Hesson; Jeong, Seo Young.
In: Infection and Immunity, Vol. 70, No. 3, 04.03.2002, p. 1143-1149.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres
AU - Seo, Jun Young
AU - Seong, Seung Yong
AU - Ahn, Byung-Yoon
AU - Kwon, Ick Chan
AU - Chung, Hesson
AU - Jeong, Seo Young
PY - 2002/3/4
Y1 - 2002/3/4
N2 - The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.
AB - The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.
UR - http://www.scopus.com/inward/record.url?scp=0036176042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036176042&partnerID=8YFLogxK
U2 - 10.1128/IAI.70.3.1143-1149.2002
DO - 10.1128/IAI.70.3.1143-1149.2002
M3 - Article
C2 - 11854194
AN - SCOPUS:0036176042
VL - 70
SP - 1143
EP - 1149
JO - Infection and Immunity
JF - Infection and Immunity
SN - 0019-9567
IS - 3
ER -